114 related articles for article (PubMed ID: 7924868)
1. [A clinical study on the tumor associated antigen CA50 in the monitoring of genitourinary malignancies].
Li CL; Xu BZ; Chen ZZ
Zhonghua Zhong Liu Za Zhi; 1994 Mar; 16(2):148-51. PubMed ID: 7924868
[TBL] [Abstract][Full Text] [Related]
2. [Clinical value of carbohydrate antigen 50 and carbohydrate antigen 242 in the diagnosis of colorectal carcinoma].
Huang CW; Bai L
Di Yi Jun Yi Da Xue Xue Bao; 2002 Dec; 22(12):1116-8. PubMed ID: 12480590
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC
Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358
[TBL] [Abstract][Full Text] [Related]
4. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
Huang C; Bei L; Liu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693
[TBL] [Abstract][Full Text] [Related]
5. The use of CA-50 radioimmunoassay test in diagnosis of urologic malignancy. Tie for second place Jobst award.
Hershman MJ; Habib NA; Ferro MA; Williamson RC; Wood CB
Am Surg; 1987 Dec; 53(12):691-4. PubMed ID: 3480697
[TBL] [Abstract][Full Text] [Related]
6. The value of squamous cell carcinoma antigen in the prognostic evaluation, treatment monitoring and followup of patients with penile cancer.
Zhu Y; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ
J Urol; 2008 Nov; 180(5):2019-23. PubMed ID: 18801542
[TBL] [Abstract][Full Text] [Related]
7. [The detection of laryngeal carcinoma-associated antigens in tissue and serum using three mixed monoclonal antibodies against laryngeal cancer].
Chen O; Guan G; Jin C
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1996; 31(1):43-6. PubMed ID: 9275404
[TBL] [Abstract][Full Text] [Related]
8. [Serological test of carbohydrate antigen CA50 in patients with cancer of the digestive tract].
Takami H; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1987 Feb; 14(2):495-501. PubMed ID: 3468885
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for Bladder Cancer.
Bonner RB; Liebert M; Hurst RE; Grossman HB; Bane BL; Hemstreet GP
Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):971-8. PubMed ID: 8959319
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of serum SCC Ag in patients with squamous cell carcinoma of the lung].
Zeng L
Zhonghua Wai Ke Za Zhi; 1993 Mar; 31(3):143-5. PubMed ID: 8223022
[TBL] [Abstract][Full Text] [Related]
12. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
[TBL] [Abstract][Full Text] [Related]
14. Sialyl Lewis-Xi antigen in patients with gynecologic tumors.
Inoue M; Shimizu C; Sasagawa T; Shimizu H; Saito J; Tanizawa O
Obstet Gynecol; 1989 Jan; 73(1):79-83. PubMed ID: 2909045
[TBL] [Abstract][Full Text] [Related]
15. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma.
Shvarts O; Seligson D; Lam J; Shi T; Horvath S; Figlin R; Belldegrun A; Pantuck AJ
J Urol; 2005 Mar; 173(3):725-8. PubMed ID: 15711252
[TBL] [Abstract][Full Text] [Related]
16. [Advances regarding tumor markers in bladder cancer].
Moreno Sierra J; Chicharro Almarza GJ; Torronteras Santiago JM; Ortega Heredia MD; Maestro de las Casas ML; Silmi Moyano A; Resel Estévez L
Actas Urol Esp; 1997 Mar; 21(3):195-205. PubMed ID: 9324884
[TBL] [Abstract][Full Text] [Related]
17. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of serum squamous cell carcinoma antigen in the management of sinonasal inverted papilloma.
Yasumatsu R; Nakashima T; Masuda M; Kuratomi Y; Shiratsuchi H; Hirakawa N; Tomita K; Yamamoto T; Komune S
Head Neck; 2005 Jan; 27(1):44-8. PubMed ID: 15459916
[TBL] [Abstract][Full Text] [Related]
19. The relationship between serial measurements of the level of a bladder tumor associated antigen and the potential for recurrence.
Blumenstein BA; Ellis WJ; Ishak LM
J Urol; 1999 Jan; 161(1):57-60; discussion 60-1. PubMed ID: 10037368
[TBL] [Abstract][Full Text] [Related]
20. [Tumor bladder antigen (TBA). A new method for the diagnosis and detection of recurrence of bladder cancer].
Escaf Barmadah S; Martín Benito JL; Fernández Gómez JM; San Martín Blanco A; Pérez Gracia FJ; Rodríguez Martínez JJ
Arch Esp Urol; 1998 Mar; 51(2):129-36. PubMed ID: 9586309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
